Sign in

CIK 0001652130 · Large accelerated filer

Intellia Therapeutics, Inc.

Sign in to watch
Ticker
NTLA
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
364785571
Phone
857-285-6200
Business address
400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
  1. 4 Open-market sale EVP, Chief Scientific Officer sold 31 shares at $17.38 ($539)
  2. 4 Open-market sale VP, Chief Accounting Officer sold 1,871 shares at $17.38 ($32,518)
  3. 8-K Event Regulation FD disclosure · Other events
  4. 4 Open-market buy Director bought 100,000 shares at $10.03 ($1,003,000)
  5. 10-Q Report Quarterly Report
  6. 8-K Event Results of operations · Executive or director change
  7. 4 Open-market sale EVP, Chief Financial Officer sold 7,462 shares at $14.02 ($104,617)
  8. 4 Open-market sale EVP, Chief Technical Officer sold 1,022 shares at $9.82 ($10,036)
  9. 4 Open-market sale VP, Chief Accounting Officer sold 2,503 shares at $9.95 ($24,905)
  10. 4 Planned sale Director sold 3,094 shares at an average $9.40 ($29,068)
  11. 4 Grant or award Director acquired 8,000 shares (grant or award)
  12. 8-K Event Regulation FD disclosure · Other events
  13. 4 Grant or award Director acquired 8,000 shares (grant or award)
  14. 4 Grant or award Director acquired 8,000 shares (grant or award)
  15. 4 Grant or award Director acquired 8,000 shares (grant or award)
  16. 4 Grant or award Director acquired 8,000 shares (grant or award)
  17. 4 Grant or award Director acquired 8,000 shares (grant or award)
  18. 4 Grant or award Director acquired 8,000 shares (grant or award)
  19. 8-K Event Executive or director change · Shareholder vote results
  20. S-8 Other Securities Offered to Employees in Benefit Plans

Page 5 of 37 · 725 filings